Eurizon Capital SGR S.p.A. Acquires New Shares in Insulet Corporation $PODD

Eurizon Capital SGR S.p.A. acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 27,215 shares of the medical instruments supplier’s stock, valued at approximately $7,741,000.

Several other large investors have also recently bought and sold shares of the company. Larson Financial Group LLC increased its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. Elyxium Wealth LLC bought a new position in Insulet in the 4th quarter worth about $28,000. Fideuram Asset Management Ireland dac bought a new position in Insulet in the 4th quarter worth about $41,000. Measured Wealth Private Client Group LLC bought a new position in Insulet in the 3rd quarter worth about $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet in the 2nd quarter worth about $51,000.

Insulet Price Performance

Shares of Insulet stock opened at $144.94 on Monday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $10.04 billion, a PE ratio of 33.71, a price-to-earnings-growth ratio of 1.14 and a beta of 1.13. The business’s 50-day moving average price is $183.55 and its 200-day moving average price is $244.77. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.44 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PODD shares. BTIG Research decreased their target price on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, May 26th. Citigroup decreased their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday. Robert W. Baird decreased their target price on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Oppenheimer decreased their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.